<p>尋找健康相關的長期持有股票的投資者不必再尋找其他地方，這個列表中的股票是醫療保健領域的市場領導者，具有可持續增長、健康的資產負債表、令人印象深刻的價值和廣泛的市場支持。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<h2><strong>雅培是長期投資的首選健康股票</strong></h2>
<p>亞利桑那州立大學金融教授亨德里克·貝森拜德的研究發現，<strong>雅培 NYSE: ABT</strong> 是自大蕭條以來回報最高的醫療保健股票。他的研究集中在複合回報上，發現雅培是整體回報第 11 高的股票，在醫療保健領域排名第一，年化複合回報率為 13.85%。報告的關鍵結論是時間的重要性。有些股票可能增長更快，但無法在長期內維持這種速度。雅培是一家經過驗證的贏家，專注於長期發展。</p>
<p>雅培的增長軌跡得益於健康的產品組合，包括成熟的製藥產品、多樣化以及強大的產品管道，確保增長能夠持續。2024 年，領先的細分市場是醫療設備，該細分市場在第三季度增長了 11.7%，實現了超預期的季度業績。診斷和營養細分市場均略有收縮，預計在 2025 財年將恢復增長。包括 COVID-19 和剝離在內的一次性因素影響了診斷和營養細分市場：調整影響後，兩者均實現了有機增長。</p>
<p>雅培的資本回報計劃包括股息和回購。回購雖然不算強勁，但足以抵消稀釋；股息才是關鍵。雅培的股息在 2024 年將達到 2.20 美元，預計在 2025 年將以低雙位數的幅度增長。股息覆蓋率充足，派息比率低於 50%，預計收益將增長。資產負債表健康，槓桿率低，現金和資本充足，能夠支持產品管道和收購投資。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png"/></p>
<h2><strong>直覺外科是投資者的明智選擇</strong></h2>
<h3>直覺外科市場排名™ 股票分析</h3>
<p><strong>整體市場排名™****97 百分位</strong></p>
<p>分析師評級 <strong>適度買入</strong></p>
<p>上漲/下跌 <strong>0.5% 下跌</strong></p>
<p>空頭頭寸水平 <strong>健康</strong></p>
<p>股息強度 <strong>不適用</strong></p>
<p>環境評分 <strong>-1.15</strong></p>
<p>新聞情緒 **0.78</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRyZ2PTI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRyZ2PTI"/></p>
<p>**</p>
<p>內部交易 <strong>出售股份</strong></p>
<p>預計收益增長 <strong>15.65%</strong></p>
<p>查看完整分析</p>
<p><strong>直覺外科 NASDAQ: ISRG</strong> 是醫療技術領域的領先公司。公司的業績表明，其達芬奇手術機器人在行業中處於領先地位。第三季度的業績遠超競爭對手，收入增長了 17%，得益於強勁的順風因素。這些順風因素包括不斷擴大的達芬奇平台安裝基礎、日益增加的批准和不斷增長的比較基數。比較基數由擴大的基礎、增加的批准和服務的深入滲透驅動，預計這種趨勢將持續多年。手術系統簡化了手術過程，併為新的應用打開了大門，包括人工智能輔助和遠程操作的手術。</p>
<p>直覺外科不向股東返還資本；相反，它選擇重新投資於業務並通過增長提供價值。關鍵細節在於資產負債表，2024 年顯示現金增加，各類資產增加，負債穩定，槓桿率極低，股東權益增長 17%。分析師在 2024 年的趨勢也積極，情緒被評為適度買入，目標價格上升。MarketBeat.com 報告的共識在 10 月底同比增長 50%，自第三季度報告發布以來增長 15%，修正後目標價格達到 550 到 600 美元的新歷史高點。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png"/></p>
<h2><strong>聯合健康在逆風中持續增長</strong></h2>
<p><strong>聯合健康 NYSE: UNH</strong> 面臨逆風，包括第一季度的網絡攻擊和保險業務的醫療成本同比上升。然而，儘管存在這些因素，公司仍在持續增長，得益於不斷增加的客户基礎和業務量。</p>
<p>2024 年的關鍵結論是槓桿率和運營質量的提高，這將維持強勁的現金流和健康的資本回報。資本回報包括股息和回購，至少股息每年都在增長。2024 年的股息為 8.40 美元，可靠性低於 30% 的收益，並伴隨中位數的十幾% 的年複合增長率。回購在第三季度末減少了 0.1% 的股份，並將在 2025 年繼續抵消稀釋。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png"/></p>
<p>→ 選舉警告成真…（來自波特公司）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDAyOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDAyOQ"/></p>
<h2>你現在應該投資 1000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師，以及他們每天推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

聯合健康

直覺外科

雅培

<p>這篇文章強調了三隻值得長期持有的醫療保健股票：雅培、直覺外科和聯合健康。雅培因其長期增長和強勁回報而受到關注，特別是在醫療設備領域。直覺外科在醫療科技方面表現出色，其達芬奇手術機器人帶來了顯著的收入增長。儘管面臨挑戰，聯合健康通過不斷擴大的客户基礎和可靠的股息保持增長。每家公司都展現了穩健的財務健康和戰略性的資本回報，使其成為長期投資者的有吸引力的選擇</p>

<p>Investors looking for health-related buy-and-hold stocks must look no further than this list. The stocks on this list are market leaders in healthcare, producing sustainable growth with healthy balance sheets, impressive value, and broad market support.</p>
<div class="lb-trans"><p>尋找健康相關的長期持有股票的投資者不必再尋找其他地方，這個列表中的股票是醫療保健領域的市場領導者，具有可持續增長、健康的資產負債表、令人印象深刻的價值和廣泛的市場支持。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><h2><strong>Abbott Laboratories Is the Number One Health Stock for Long-Term Investment</strong></h2>
<div class="lb-trans"><h2><strong>雅培是長期投資的首選健康股票</strong></h2>
</div><p>study by Arizona State finance professor Hendrik Bessembinder found that <strong>Abbott Laboratories NYSE: ABT</strong> is the top-returning healthcare stock since the Great Depression. His study focused on compound returns, finding Abbott the 11th top-returning stock overall and #1 in healthcare with an annualized compound return of 13.85%. The key takeaway from the report is that time is important. Some stocks may grow faster but cannot sustain the pace over the long term. Abbott is a proven winner, focused on the long term.</p>
<div class="lb-trans"><p>亞利桑那州立大學金融教授亨德里克·貝森拜德的研究發現，<strong>雅培 NYSE: ABT</strong> 是自大蕭條以來回報最高的醫療保健股票。他的研究集中在複合回報上，發現雅培是整體回報第 11 高的股票，在醫療保健領域排名第一，年化複合回報率為 13.85%。報告的關鍵結論是時間的重要性。有些股票可能增長更快，但無法在長期內維持這種速度。雅培是一家經過驗證的贏家，專注於長期發展。</p>
</div><p>Abbott’s growth trajectory is sustained by a healthy portfolio that includes established pharmaceuticals, diversification, and a robust pipeline that ensures growth can be sustained. In 2024, the leading segment is Medical Devices, which grew by 11.7% in Q3 to produce a beat-and-raise quarter. Diagnostics and Nutrition both contracted by slim margins, with reported growth expected to resume in F2025. One-offs, including COVID-19 and divestitures, impact the diagnostic and nutrition segments: adjusting for the impact, both are growing organically.</p>
<div class="lb-trans"><p>雅培的增長軌跡得益於健康的產品組合，包括成熟的製藥產品、多樣化以及強大的產品管道，確保增長能夠持續。2024 年，領先的細分市場是醫療設備，該細分市場在第三季度增長了 11.7%，實現了超預期的季度業績。診斷和營養細分市場均略有收縮，預計在 2025 財年將恢復增長。包括 COVID-19 和剝離在內的一次性因素影響了診斷和營養細分市場：調整影響後，兩者均實現了有機增長。</p>
</div><p>Abbott’s capital return program includes dividends and repurchases. The repurchases aren’t robust but sufficient to offset dilution; the dividend is what counts. Abbott’s dividend will be worth $2.20 in 2024 and is expected to grow by a low double-digit amount in 2025. The dividend coverage is ample, with the payout ratio below 50% and earnings forecasted to grow. The balance sheet is healthy, with low leverage and sufficient cash and capitalization to sustain pipeline and acquisitional investment.</p>
<div class="lb-trans"><p>雅培的資本回報計劃包括股息和回購。回購雖然不算強勁，但足以抵消稀釋；股息才是關鍵。雅培的股息在 2024 年將達到 2.20 美元，預計在 2025 年將以低雙位數的幅度增長。股息覆蓋率充足，派息比率低於 50%，預計收益將增長。資產負債表健康，槓桿率低，現金和資本充足，能夠支持產品管道和收購投資。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png"/></p>
<h2><strong>Intuitive Surgical Is an Intuitive Buy for Investors</strong></h2>
<div class="lb-trans"><h2><strong>直覺外科是投資者的明智選擇</strong></h2>
</div><h3>Intuitive Surgical MarketRank™ Stock Analysis</h3>
<div class="lb-trans"><h3>直覺外科市場排名™ 股票分析</h3>
</div><p><strong>Overall MarketRank™****97th Percentile</strong></p>
<div class="lb-trans"><p><strong>整體市場排名™****97 百分位</strong></p>
</div><p>Analyst Rating<strong>Moderate Buy</strong></p>
<div class="lb-trans"><p>分析師評級 <strong>適度買入</strong></p>
</div><p>Upside/Downside<strong>0.5% Downside</strong></p>
<div class="lb-trans"><p>上漲/下跌 <strong>0.5% 下跌</strong></p>
</div><p>Short Interest Level<strong>Healthy</strong></p>
<div class="lb-trans"><p>空頭頭寸水平 <strong>健康</strong></p>
</div><p>Dividend Strength<strong>N/A</strong></p>
<div class="lb-trans"><p>股息強度 <strong>不適用</strong></p>
</div><p>Environmental Score**-1.15**</p>
<div class="lb-trans"><p>環境評分 <strong>-1.15</strong></p>
</div><p>News Sentiment**0.78</p>
<div class="lb-trans"><p>新聞情緒 **0.78</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRyZ2PTI" alt="" original-src="https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx?Prefix=NASDAQ&amp;Symbol=ISRG&amp;v=2"/></p>
<p>**</p>
<div class="lb-trans"><p>**</p>
</div><p>Insider Trading<strong>Selling Shares</strong></p>
<div class="lb-trans"><p>內部交易 <strong>出售股份</strong></p>
</div><p>Proj. Earnings Growth<strong>15.65%</strong></p>
<div class="lb-trans"><p>預計收益增長 <strong>15.65%</strong></p>
</div><p>See Full Analysis</p>
<div class="lb-trans"><p>查看完整分析</p>
</div><p><strong>Intuitive Surgical NASDAQ: ISRG</strong> is the leading pure-play on MedTech. The company’s results show that its da Vinci surgical robots lead the field. The Q3 results were head-&amp;-shoulders above the competition, with a 17% increase in revenue driven by strong tailwinds. The tailwinds include an expanding installed base of da Vinci platforms, widening approval, and growing comps. Comps are driven by the expanded base, increased approvals, and deepening penetration of services, which are expected to continue for many years. The surgical systems simplify surgeries and open the door to new applications, including AI assistance and procedures performed from remote locations.</p>
<div class="lb-trans"><p><strong>直覺外科 NASDAQ: ISRG</strong> 是醫療技術領域的領先公司。公司的業績表明，其達芬奇手術機器人在行業中處於領先地位。第三季度的業績遠超競爭對手，收入增長了 17%，得益於強勁的順風因素。這些順風因素包括不斷擴大的達芬奇平台安裝基礎、日益增加的批准和不斷增長的比較基數。比較基數由擴大的基礎、增加的批准和服務的深入滲透驅動，預計這種趨勢將持續多年。手術系統簡化了手術過程，併為新的應用打開了大門，包括人工智能輔助和遠程操作的手術。</p>
</div><p>Intuitive Surgical does not return capital to shareholders; instead, it chooses to reinvest in the business and provide value with growth. The critical details are in the balance sheet, which 2024 shows increasing cash, increased assets in all categories, steady liability, ultra-low leverage, and a 17% increase in shareholder equity. Analysts' trends in 2024 are also positive, with sentiment pegged at Moderate Buy and the price target increasing. The consensus reported by MarketBeat.com is up 50% YoY in late October, up 15% since the Q3 report was released, with revisions leading to a new all-time high in the $550 to $600 range.</p>
<div class="lb-trans"><p>直覺外科不向股東返還資本；相反，它選擇重新投資於業務並通過增長提供價值。關鍵細節在於資產負債表，2024 年顯示現金增加，各類資產增加，負債穩定，槓桿率極低，股東權益增長 17%。分析師在 2024 年的趨勢也積極，情緒被評為適度買入，目標價格上升。MarketBeat.com 報告的共識在 10 月底同比增長 50%，自第三季度報告發布以來增長 15%，修正後目標價格達到 550 到 600 美元的新歷史高點。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png"/></p>
<h2><strong>UnitedHealth Group Grows Despite Headwinds</strong></h2>
<div class="lb-trans"><h2><strong>聯合健康在逆風中持續增長</strong></h2>
</div><p><strong>UnitedHealth Group NYSE: UNH</strong> has headwinds, including the cyber attack in Q1 and higher YoY medical costs for its insurance business. However, despite those factors, the company is sustaining growth, supported by an increasing client base and volume.</p>
<div class="lb-trans"><p><strong>聯合健康 NYSE: UNH</strong> 面臨逆風，包括第一季度的網絡攻擊和保險業務的醫療成本同比上升。然而，儘管存在這些因素，公司仍在持續增長，得益於不斷增加的客户基礎和業務量。</p>
</div><p>The critical takeaways from 2024 are the increased leverage and operational quality, which will sustain robust cash flow and a healthy capital return. The capital return includes dividends and repurchases, and the dividend, at least, is growing annually. The dividend is worth $8.40 in 2024, is reliable at less than 30% of earnings, and comes with a mid-teens CAGR. The repurchases reduced the count by 0.1% YTD at the end of Q3 and will continue to offset dilution in 2025.</p>
<div class="lb-trans"><p>2024 年的關鍵結論是槓桿率和運營質量的提高，這將維持強勁的現金流和健康的資本回報。資本回報包括股息和回購，至少股息每年都在增長。2024 年的股息為 8.40 美元，可靠性低於 30% 的收益，並伴隨中位數的十幾% 的年複合增長率。回購在第三季度末減少了 0.1% 的股份，並將在 2025 年繼續抵消稀釋。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png"/></p>
<p>→ Election warning coming true… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 選舉警告成真…（來自波特公司）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDAyOQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10029&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Abbott Laboratories right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師，以及他們每天推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

這些是適合長期持有投資的頂級健康股票